Actualités

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

European equities traded in the US as American depositary receipts started the week higher late Mond

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

The package delivery giant is building out 27 temperature-controlled facilities across three continents as demand for refrigerated pharmaceuticals grows

With a short percentage of shares outstanding of 0.51%, Novo Nordisk A/S (NYSE:NVO) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares. Earlier, on […]

UK GLP-1 users are shifting spending toward high-protein foods, vitamins and fitness products.

F5 surged after a Zacks Rank upgrade, while Atlanticus and Starbucks posted notable gains as several Zacks strategies outperformed.

The approval of the first oral pill this month will drive a more powerful shift in consumer habits, PwC found in a study.

Novo Nordisk A/S is investigating claims by cyber extortion group FulcrumSec, which alleges it stole more than a terabyte of data from the pharmaceutical company and is considering selling portions of the information after an unsuccessful $25 million ransom demand. FulcrumSec Claims Months-Long Access To Company Systems Citing a message posted by FulcrumSec on Tuesday, Reuters reported that the group spent more than two months inside Novo Nordisk’s networks collecting data. The hackers claimed t

Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...

Novo Nordisk Foundation has launched CardioMetabolic Bridge, a pan-European initiative focused on translating cardiometabolic research into commercial therapies. The program targets new treatments for obesity, diabetes, and cardiovascular disease, with funding spread over six years and across multiple European countries. The effort aims to move early-stage academic work closer to clinical testing and potential commercial use. Novo Nordisk (CPSE:NOVO B) enters this development with the stock...

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Novo Nordisk Owner Bets Big on Obesity Breakthroughs With New $69 Million Program

Novo Nordisk Foundation commits up to EUR 60 million for drug discovery projects

Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a target of DKK290, just 3.6% above the last closing price of DKK280.10, and maintains a hold...

The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.

June 19 (Reuters) - European shares inched higher on Friday, aided by gains in energy and healthcare stocks as investors remained cautious after U.S.-Iran negotiations to end the Middle conflict

By Stella Qiu SYDNEY, June 19 (Reuters) - Asian shares reversed course and fell on Friday as investors took some money off the table from record rallies in Japan and South Korea, while signs of an

Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.

Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.

Novo Nordisk (NYSE:NVO) is seeing strong uptake of its oral Wegovy treatment, with the tablet formulation accounting for roughly one-third of all Wegovy prescriptions by May, according to a Bank of America report published on Thursday. The data highlights the rapid adoption of the oral version since its market debut earlier this year and underscores continued momentum across the broader GLP-1 weight-loss drug market.

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.